Search

Meeting Coverage:

Association for Research in Vision & Ophthalmology

ARVO: 2025

Phase 2 Data on Gene Therapy for AMD

Christine Kay, MD

Show Description +

Dr. Kay discusses the interim results from the phase 2b extension cohort in the PRISM clinical trial of 4D-150 (4DMT) for the treatment of wet AMD.

Posted: 5/16/2025

Keywords:

retina-meeting-recap

•

4DMT

•

Clinical Trials

•

Age-Related Macular Degeneration (AMD)

•

Wet AMD

•

4D-150

Up Next

OCS-01 (Oculis) in DME: A Phase 3 Update

OCS-01 (Oculis) in DME: A Phase 3 Update

Carl Danzig, MD

Gene Therapy for Wet AMD: New Phase 2 Data

Gene Therapy for Wet AMD: New Phase 2 Data

Dante Pieramici MD

Surgical Pearls for Sickle Cell Retinopathy

Surgical Pearls for Sickle Cell Retinopathy

Jennifer I. Lim, MD

Dosing Considerations with 8 mg Aflibercept

Dosing Considerations with 8 mg Aflibercept

Mark R. Barakat, MD

Pegcetacoplan in the Real World: Year 1

Pegcetacoplan in the Real World: Year 1

Mengxi Shen, MD, PhD

Phase 2a Data Revealed for AVD-104 (Aviceda)

Phase 2a Data Revealed for AVD-104 (Aviceda)

Baruch D. Kuppermann, MD, PhD

Real-World Data for 8 mg Aflibercept

Real-World Data for 8 mg Aflibercept

Vasileios Konidaris, MD, PhD

$The Benefits of Refractive Vitrectomy for SVOs$

The Benefits of Refractive Vitrectomy for SVOs

Paulo Eduardo Stanga, MD

Bariatric Surgery Versus GLP-1 Receptor Agonists

Bariatric Surgery Versus GLP-1 Receptor Agonists

Christabel Chan, MD

Treating DR with Axitinib

Treating DR with Axitinib

Neal S. Shah, MD

Back to All Videos

Phase 2 Data on Gene Therapy for AMD

Christine Kay, MD

Dr. Kay discusses the interim results from the phase 2b extension cohort in the PRISM clinical trial of 4D-150 (4DMT) for the treatment of wet AMD.

Posted: 5/16/2025

Keywords:

retina-meeting-recap

•

4DMT

•

Clinical Trials

•

Age-Related Macular Degeneration (AMD)

•

Wet AMD

•

4D-150

Please log in to leave a comment.

More From ARVO: 2025 Coverage

Phase 2a Data Revealed for AVD-104 (Aviceda)

Phase 2a Data Revealed for AVD-104 (Aviceda)

Baruch D. Kuppermann, MD, PhD

Real-World Data for 8 mg Aflibercept

Real-World Data for 8 mg Aflibercept

Vasileios Konidaris, MD, PhD

$The Benefits of Refractive Vitrectomy for SVOs$

The Benefits of Refractive Vitrectomy for SVOs

Paulo Eduardo Stanga, MD

Bariatric Surgery Versus GLP-1 Receptor Agonists

Bariatric Surgery Versus GLP-1 Receptor Agonists

Christabel Chan, MD

Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of ARVO: 2025.